{
    "Trade/Device Name(s)": [
        "LIAISON\u00ae Rubella IgM",
        "LIAISON\u00ae Control Rubella IgM"
    ],
    "Submitter Information": "DiaSorin Inc.",
    "510(k) Number": "K122397",
    "Predicate Device Reference 510(k) Number(s)": [
        "K010668"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LFX",
        "JJX"
    ],
    "Summary Letter Date": "August 6, 2012",
    "Summary Letter Received Date": "August 7, 2012",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 866.3510",
        "21 CFR 862.1660"
    ],
    "Regulation Name(s)": [
        "Rubella Virus Serological Reagents",
        "Quality control material"
    ],
    "Analyte Class(es)": [
        "microbiology",
        "immunology",
        "serology"
    ],
    "Analyte(s)": [
        "IgM antibodies to rubella virus"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "LIAISON\u00ae Analyzer family of instruments"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent immunoassay (CLIA)"
    ],
    "Methodologies": [
        "Immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for LIAISON\u00ae Rubella IgM and Control Rubella IgM using CLIA technology for qualitative determination of anti-rubella IgM antibodies",
    "Indications for Use Summary": "Qualitative determination of IgM antibodies to rubella virus in human serum as an aid in diagnosis of current or recent rubella infection, including in women of child bearing age; controls for monitoring assay performance.",
    "fda_folder": "Microbiology"
}